fuov1 cell line (DSMZ)
DSMZ is a verified supplier 
90
Structured Review
DSMZ
fuov1 cell line
Fuov1 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fuov1/fu+ov1+line/pmc11962063-313-3-16
Average 90 stars, based on 1 article reviews
Fuov1 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fuov1/fu+ov1+line/pmc11962063-313-3-16
Average 90 stars, based on 1 article reviews
fuov1 cell line - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR"
Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Journal: Nature Communications
doi: 10.1038/s41467-025-58183-w
Figure Legend Snippet: A QIBC quantitation of FT282-hTERT p53 R175H parental (WT, left) and CCNE1 -overexpressing ( CCNE1 -O/E, right) EdU - /pan-γH2AX + cell in response to the indicated RP-6306/RP-3500 combinations treated for 48 h. n = 3; Mean + SD. B Detection of γH2AX + cells by flow cytometry in indicated cells after treated with RP-6306 (250 nM), RP-3500 (50 nM), or a combination of both treated for 24 h. n = 3; Mean + SD. C , D Whole cell lysates of OVCAR3 ( C ) and KLE ( D ) cells were treated with RP-6306 (250 nM), RP-3500 (50 nM), or both for the indicated times and immunoblotted with γH2AX and Actin antibodies. Actin is loading control. E Representative micrographs (left) of metaphase spreads from FT282 parental (WT) and CCNE1- overexpressing cells left untreated or following treatment with combination of RP-6306 (125 nM) and RP-3500 (25 nM) for 24 h and quantitation of cells (right) after 24 h treatment with the indicated RP-6306 (125 nM) and RP-3500 (25 nM) conditions with at least 40 metaphases counted per replicates. n = 3; Mean + SD. F OVCAR3 tumor-bearing mice were administered RP-6306 (5 mg/kg) orally BID, RP-3500 (5 mg/kg) orally QD or a combination of both for 3 days, sacrificed 2 h post last treatment, and tumor tissue was prepared for FFPE. Tumor tissues were stained with γH2AX antibodies (left), and the percentage of γH2AX 3 + strong positive tissue (right) present in the tumor area was quantified by HALO software, n = 6,5,5,5;); Mean + SD. Scale bar: 100 µm. G WU-115 were administered RP-6306 (10 mg/kg) orally BID, RP-3500 (5 mg/kg) orally QD or a combination of both for 10 days, sacrificed 2 h post last treatment and tumor tissue was prepared for FFPE. Tumor tissues were stained with γH2AX antibodies (left), and the percentage of γH2AX 3 + strong positive tissue (right) present in the tumor area was quantified by HALO software. n = 6,5,5,5; Mean + SD. Scale bar: 100 µm. Red arrows illustrate γH2AX 3 + strong positive cells quantified ( H ) Flow cytometry quantification of apoptotic cells with Annexin V and propidium iodide (PI) staining of the indicated cells after treated with drugs RP-6306 (250 nM), RP-3500 (50 nM), or both for 72 hrs. n = 3; Mean + SD ( I ) SNU685 CCNE1 inducible cells were treated and detected with apoptotic cells same as ( G ). n = 3; Mean + SD. J , K Whole cell lysates of OVCAR3 ( J ) and KLE ( K ) cells were treated with RP-6306 (250 nM), RP-3500 (50 nM), or both for the indicated times and immunoblotted with cleaved PARP (cPARP), cleaved caspase 9 (cCas9), cleaved caspase 93 (cCas3), and Actin antibodies. Actin is loading control. Significance determined by two-way ANOVA followed by Tukey’s multiple comparisons test for ( A , B , E , H , I ) and one-way ANOVA followed by Tukey’s multiple comparisons for OVCAR3 and WU-115 xenograft in ( F , G ).
Techniques Used: Quantitation Assay, Flow Cytometry, Control, Staining, Software
Figure Legend Snippet: A QIBC quantitation of FT282-hTERT p53 R175H parental (WT, left) CCNE1 -overexpressing ( CCNE1 -O/E, middle) and OVCAR3 (right) cells with percent of EdU + /cyclin B-pS126 + as a function of time after addition of RP-6306 (250 nM), RP-3500 (100 nM) or combination of both. B Whole cell lysates of FT282-hTERT p53 R175H CCNE1-overexpressing ( CCNE1 -O/E) cells treated with RP-3500 (100 nM), RP-6306 (250 nM) or both for the indicated times were immunoblotted with CDK1, CDK1-pT14, CHK1, CHK1-pS345, CDC25B, CDC25B-pS151 and Actinin specific antibodies Actinin is used as loading control. C , D Whole cell lysates of KLE (C) and OVCAR3 (D) cells treated with RP-6306 (250 nM), RP-3500 (50 nM), or both for the indicated times were immunoblotted with CDK1, CDK1-pT14, CHK1, CHK1-pS345 and Actin specific antibodies. E , F Tumor tissue from WO-77 ( E ) tumor-bearing mice from Fig. at end of treatment or WU-115 ( F ) tumor-bearing mice administered RP-6306 (10 mg/kg) orally BID, RP-3500 (5 mg/kg) orally QD or combination of both for 10 days and sacrificed 2 h post last treatment was prepared for FFPE Tumor tissues were stained with CDK1-pT14 antibodies (left) and the percentage of CDK1-pT14 strong-positive tissue (right) present in the tumor area was quantified by HALO software. n = 3,3,3,3,4,4 ( E ), n = 6,5,5,5 ( F ) Mean ± SD. Scale bar: 200 µm. G Growth inhibition relative to DMSO control of RPE1-hTERT TP53 -/- parental, BRCA1 -/- , ATM -/- and CCNE1-overexpressing ( CCNE1-2A-GFP ) cells after treatment with the indicated dose of RP-6306, RP-3500 or the combination of both. n = 3; Mean + SD. Significance determined by one-way ANOVA followed by Tukey’s multiple comparisons test in for ( A , E , G ), and Students’ t test in ( F ).
Techniques Used: Quantitation Assay, Control, Staining, Software, Inhibition
Related Articles
Genome Wide:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); CRISPR:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Inhibition:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Transfection:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Control:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Staining:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Extraction:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Standard Deviation:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Biomarker Discovery:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Derivative Assay:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Protein Array:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Expressing:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Western Blot:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Recombinant:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Negative Control:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Software:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Colony Assay:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Protease Inhibitor:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Membrane:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Saline:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Electron Microscopy:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); RNA Sequencing:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Cytometry:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Microscopy:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Polymer:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Virus:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Infection:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); BrdU Staining:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Flow Cytometry:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Imaging:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Plasmid Preparation:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Enzyme-linked Immunosorbent Assay:Article Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Article Snippet: OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); Article Title: Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer Article Snippet: Purpose: Ovarian cancer has the highest mortality rate of all the gynecologic malignancies and is responsible for approximately 140,000 deaths annually worldwide.. Copy number amplification is frequently associated with the activation of oncogenic drivers in this tumor type, but their cytogenetic complexity and heterogeneity has made it difficult to determine which gene(s) within an amplicon represent(s) the genuine oncogenic driver.. We sought to identify amplicon targets by conducting a comprehensive functional analysis of genes located in the regions of amplification in high-grade serous and endometrioid ovarian tumors. Article Title: UBA1 inhibition sensitizes cancer cells to PARP inhibitors Article Snippet: Article Title: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Article Snippet: Cell lines and primary cells OVCAR3, FUOV1, and KLE cell lines were purchased from ATCC (Manassas, Virginia); |